Alexion Pharmaceuticals (ALXN) Lowered to “Hold” at BidaskClub

BidaskClub cut shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from a buy rating to a hold rating in a research report released on Thursday, March 21st, BidAskClub reports.

Several other research firms also recently weighed in on ALXN. Cowen reissued a buy rating and issued a $165.00 price target on shares of Alexion Pharmaceuticals in a research note on Wednesday, March 13th. Credit Suisse Group reissued a buy rating and issued a $156.00 price target on shares of Alexion Pharmaceuticals in a research note on Tuesday, January 22nd. Morgan Stanley lifted their target price on shares of Alexion Pharmaceuticals from $165.00 to $175.00 and gave the stock an overweight rating in a research note on Tuesday, February 12th. Raymond James reaffirmed a buy rating on shares of Alexion Pharmaceuticals in a research note on Sunday, December 30th. Finally, Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Monday, December 31st. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $162.06.

Shares of NASDAQ:ALXN traded up $1.29 during midday trading on Thursday, reaching $137.49. The company’s stock had a trading volume of 855,300 shares, compared to its average volume of 1,563,556. The firm has a market capitalization of $30.58 billion, a P/E ratio of 19.39, a PEG ratio of 1.05 and a beta of 1.55. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.88 and a quick ratio of 2.48. Alexion Pharmaceuticals has a twelve month low of $92.56 and a twelve month high of $141.86.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Monday, February 4th. The biopharmaceutical company reported $2.14 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.60 by $0.54. The company had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.06 billion. Alexion Pharmaceuticals had a net margin of 1.88% and a return on equity of 18.15%. The firm’s revenue was up 24.1% on a year-over-year basis. During the same quarter last year, the business earned $1.48 earnings per share. Equities analysts anticipate that Alexion Pharmaceuticals will post 8.51 EPS for the current fiscal year.

In related news, CAO Daniel Bazarko sold 2,000 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Thursday, February 14th. The shares were sold at an average price of $126.00, for a total value of $252,000.00. Following the completion of the transaction, the chief accounting officer now owns 5,020 shares in the company, valued at $632,520. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.08% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ALXN. Wedbush Securities Inc. lifted its position in shares of Alexion Pharmaceuticals by 1.5% during the 4th quarter. Wedbush Securities Inc. now owns 5,467 shares of the biopharmaceutical company’s stock worth $532,000 after buying an additional 83 shares during the last quarter. Utah Retirement Systems lifted its position in shares of Alexion Pharmaceuticals by 0.3% during the 4th quarter. Utah Retirement Systems now owns 39,903 shares of the biopharmaceutical company’s stock worth $3,885,000 after buying an additional 100 shares during the last quarter. Louisiana State Employees Retirement System lifted its position in shares of Alexion Pharmaceuticals by 0.9% during the 1st quarter. Louisiana State Employees Retirement System now owns 11,800 shares of the biopharmaceutical company’s stock worth $1,595,000 after buying an additional 100 shares during the last quarter. Nuveen Asset Management LLC lifted its position in shares of Alexion Pharmaceuticals by 1.8% during the 4th quarter. Nuveen Asset Management LLC now owns 6,181 shares of the biopharmaceutical company’s stock worth $602,000 after buying an additional 110 shares during the last quarter. Finally, Kaizen Advisory LLC lifted its position in shares of Alexion Pharmaceuticals by 22.2% during the 4th quarter. Kaizen Advisory LLC now owns 610 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 111 shares during the last quarter. Institutional investors own 95.01% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Story: What is a front-end load?

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.